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Abstract Macrophages are crucial for the development of
atherosclerotic plaques. Classically activated macrophages
contribute to plaque growth and destabilization, while alter-
natively activated macrophages increase plaque stability.
Here, we assessed the influence of ezetimibe on the activation
of monocyte-derived macrophages isolated from patients with
hypercholesterolemia (total cholesterol 263.4±12.5 mg/dl,
low-density lipoprotein cholesterol 179.7±11.3 mg/dl, tri-
glycerides 123.9±11.4 mg/dl). Cells were stimulated with
1 μg/ml lipopolysaccharide (LPS) or 1 μg/ml LPS plus
22 ng/ml ezetimibe. Control cells were left unstimulated.
The expression of classical activation markers (interleukin-
1β (IL-1β), nitric oxide (NO), and inducible nitric oxide
synthase (iNOS)) and alternative activation markers (mannose
receptor (MR) and arginase-1 (Arg1)) was determined after
48 h. The employed analytical methods included enzyme-
linked immunosorbent assay, Griess reaction, real-time poly-
merase chain reaction, and Western blotting. LPS increased
the secretion of IL-1β and NO and the expression of iNOS
mRNA, iNOS protein, and Arg1 protein. It did not affect the
expression of MR or Arg1 mRNA. In comparison to LPS
stimulation, co-stimulation with ezetimibe decreased the se-
cretion of IL-1β and the expression of iNOS mRNA and
protein, while it increasedMRmRNA and protein expression.
Co-stimulation with ezetimibe did not change the secretion of
NO or the expression of Arg1. The results suggest that
ezetimibe in inflammatory in vitro conditions contributes to
the suppression of classical and promotion of the alternative
macrophage activation.
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Introduction
Monocytes, along with granulocytes and natural killer cells,
belong to the cellular elements of the innate, nonspecific im-
mune system. Monocytes also link innate and adaptive immu-
nity through antigen presentation and cytokine production
(Auffray et al. 2009). After infiltration of surrounding tissues,
monocytes differentiate into macrophages whose primary func-
tion is to uphold homeostasis by scavenging senescent cells and
repairing injured areas undergoing inflammatory processes
(Gordon and Taylor 2005). However, macrophages do not
constitute a homogenous population. Depending on the stimu-
lus, these cells undergo different activation and consequently
present distinct properties. According to the most recent divi-
sions, there are two major types of activated macrophages: the
classically activated macrophages (M1) and the alternatively
activated macrophages (M2). In vitro, there are in total five
subpopulations: M1a, M1b, M2a, M2b, and M2c. However,
there is no certainty regarding whether they constitute separate
entities or if they represent subsequent stages of the develop-
ment continuum. The M1a and M2a macrophages have also
been identified in vivo. The existence of the other subpopula-
tions in vivo is presently of minor probability (Rees 2010).
Macrophages are key cells involved in the process of
atherogenesis (Auffray et al. 2009). As well as the differences
in the roles of the given subpopulations, they also exert
contrasting effects regarding the development and stability
of the atherosclerotic plaque (Auffray et al. 2009; Wilson
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2010). The M1 subpopulation effectively combats pathogens.
However, the M1 macrophages also promote atherosclerotic
plaque growth due to pro-inflammatory properties, damage of
tissues, and absorption of low-density lipoproteins (LDLs).
The M1 cells contribute to increased plaque vulnerability and
susceptibility to cracking, which raises the risk of thrombotic
changes, and hence this subpopulation is often called “athero-
genic.” In contrast to the M1 subpopulation, the M2 macro-
phages produce anti-inflammatory cytokines, inhibit inflam-
matory reactions, and extinguish inflammatory states. TheM2
macrophages promote tissue repair processes and stabilize
atherosclerotic plaques, even leading to their regression, and
hence the M2 macrophages are often referred to as being
“atheroprotective” (Wilson 2010). Both M1 and M2 macro-
phages produce characteristic markers that are related to their
functions. Among other markers, the M1 macrophages pro-
duce significant amounts of nitric oxide (NO) due to elevated
expression of inducible nitric oxide synthase (iNOS), which is
necessary for effective antimicrobial activity. They also se-
crete large quantities of interleukin-1β (IL-1β), a major pro-
inflammatory cytokine (Gordon and Taylor 2005). On the
other hand, the M2 macrophage subpopulation is character-
ized by increased activity of arginase-1 (Arg1), which is
crucial during the final stages of inflammatory-state
quenching. These cells also demonstrate a higher expression
of mannose receptors (MRs), resulting in changes in phago-
cytosis and membrane transport (Varin and Gordon 2009).
Considering the properties of the macrophage subpopula-
tions, investigations of the immunomodulative properties of
various pharmacologically active substances are underway.
From this point of view, the drugs used to treat hypercholes-
terolemia are of special interest. One of the newest therapeutic
agents used to treat this disease is ezetimibe, a potent choles-
terol and phytosterol absorption inhibitor that acts in the small
intestine lumen. Ezetimibe blocks the Nieman-Pick C1-Like 1
(NPC1L1) transporter protein in the brush border of
enterocytes (Suchy et al. 2011). At the daily oral dose of
10 mg, it reduces the absorption of cholesterol by about
54 % and decreases the plasma level of LDL cholesterol by
about 15–20 %. Beside the influence on lipid parameters,
ezetimibe also exerts additional effects such as reducing the
level of C-reactive protein (CRP), which is a global inflam-
matory marker (Suchy et al. 2011). Ezetimibe also directly
affects properties of monocytes and macrophages. The drug
modifies the functioning of monocyte lipid rafts and reduces
the absorption of oxidized LDLs in macrophages. In this way,
it reduces the formation of foam cells and the gathering of
lipids in the atherosclerotic plaques. Ezetimibe in macro-
phages undergoes endocytosis and, after being absorbed into
these cells, is also able to modify the expression of several
genes (Suchy et al. 2011). However, whether the drug influ-
ences macrophage activation pathways has not yet been
investigated.
The aim of this study was to assess the in vitro impact of
ezetimibe on the activation of monocyte-derivedmacrophages
isolated from patients with hypercholesterolemia and thereby





azetidin-2-one, was purchased from LKT Laboratories, Inc.
(USA). Lipopolysaccharide (LPS, Escherichia coli serotype
0111:B4), polysaccharose Histopaque 1077, dimethyl sulfox-
ide (DMSO) Hybri-Max, trypan blue 0.4 % solution, TRIzol/
TRI reagent, chloroform, isopropanol, protease inhibitor
cocktail, Bradford reagent, Laemmli sample buffer concen-
trate, 40 % bis-acrylamide, tetramethylethylenediamine
(TEMED), Trizma base (Tris), sodium dodecyl sulfate
(SDS), ammonium persulfate (APS), sodium chloride, hydro-
chloric acid, Tween 20, glycine, bovine serum albumin
(BSA), and primary rabbit anti-human antibody anti-Arg1
(307-322) were from Sigma-Aldrich Co. (USA). RPMI 1640
(without phenol red, with glutamine), 1 M 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)
buffer, Hank's balanced salt solution (HBSS; without calcium,
magnesium, and phenol red), and Dulbecco’s phosphate-
buffered saline (PBS) were bought from PAA Laboratories
GmbH (Austria). Glutamine was purchased from Gibco-BRL
(USA). Low-endotoxin fetal bovine serum (FBS), antibiotic-
antimycotic anti-anti solution, and glycogen were from
Invitrogen (USA). Absolute ethanol and methanol were
bought from Merck Millipore (Germany). Magnetic beads
(pan-T (anti-CD2) and pan-B (anti-CD19)) were purchased
from Dynal Biotech ASA (Norway). Monoclonal mouse anti-
human antibody anti-CD14 (CD14-FITC) was bought from
Thermo Fisher Scientific Inc. (USA). Nitrate/Nitrite Colori-
metric Assay Kit was purchased from Cayman Chemical
Company (USA). The enzyme-linked immunosorbent assay
(ELISA) kit for human IL-1β was from R&D Systems, Inc.
(USA). Primers (Table 1) for the real-time polymerase chain
reaction (RT-PCR) were obtained from Genomed S.A.
(Poland). Affinity Script QPCR cDNA Synthesis Kit and
PCR Brilliant II SYBR Green QPCR Master Mix with Low
ROX were purchased from Agilent Technologies (USA).
ColorPlus Prestained Protein Markers (Broad Range (97–
175 kDa) P7709V and Broad Range (10–230 kDa) P7711S)
were f r om New Eng land Bio l ab s Inc . (USA) .
Radioimmunoprecipitation assay (RIPA) lysis buffer,
SuperSignal Molecular Weight Protein Ladder, Western blot
polyvinylidene fluoride (PVDF) transfer membrane, primary
rabbit anti-human antibody anti-β-actin (PA1-21167), and
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Restore Plus Western Blot stripping buffer were from Thermo
Fisher Scientific Inc. (USA). Primary rabbit anti-human anti-
bodies anti-MR (ab64693) and anti-iNOS (ab15323) were
from Abcam (USA). Amersham ECLWestern Blotting Anal-
ysis System was purchased from GE Healthcare (UK).
Isolation of human monocytes
The study was accepted by the Bioethical Committee of the
Medical University of Silesia in Katowice, Poland. The inves-
tigation conformed to the principles of the Declaration of
Helsinki. Human whole-blood samples were taken from 20
yet untreated patients with primary hypercholesterolemia (to-
tal cholesterol 263.4±12.5 mg/dl, LDL cholesterol 179.7±
11.3 mg/dl, triglycerides 123.9±11.4 mg/dl) registered at the
Independent Public Central Clinical Hospital of the Medical
University of Silesia in Katowice, Poland (Table 2). Later
therapy of the patients was not altered as the samples were
taken only once. Peripheral blood monocytic cells (PBMCs)
were obtained by density-gradient centrifugation using
polysaccharose (Okopień et al. 2005). Monocytes were iso-
lated from the mixed population of PBMCs using the negative
immunomagnetic method (Flø et al. 1991), which excludes T,
B, and NK cells with magnetic beads coated with the relevant
antibodies. The mean (±standard deviation, SD) purity of the
obtained monocytes determined by fluorescent antibody la-
beling with anti-CD14 was 92.02±2.37 %. Next, the mono-
cytes obtained from each of the patients were diluted in HBSS
containing 2 % (v/v) FBS to obtain a cell density of 1×106/ml.
Three 1-ml suspension portions were placed in a 24-well
culture dish (Nunclon Delta Surface, Nunc, Denmark) and
incubated for 3 h at 37 °C in air containing 5.2 % (v/v) carbon
dioxide and 95 % (v/v) relative humidity in order to allow the
monocytes to adhere. After that time, the cells were gently
washed to remove the remaining nonadherent cells. Three
wells containing cells from one patient constituted one series
of cultures. The cells in each of the wells underwent different
stimulations.
Cell cultures
Monocytes were cultured in RPMI 1640 supplemented with
10 % (v/v) FBS, 25 mM HEPES, 2 mM glutamine, 100 U/ml
penicillin, 100 μg/ml streptomycin, and 10 μg/ml
amphotericin B as in the above conditions. The cells were
adapted to the conditions for 24 h, after which the medium
was replaced with either (1) regular medium, (2) medium
supplemented with 1 μg/ml (submaximal dose) LPS, or (3)
medium supplemented with 1 μg/ml LPS plus 22 ng/ml
ezetimibe. The concentration of ezetimibe was equivalent to
that measured in the serum of patients chronically taking the
drug at the oral daily dose of 10 mg (Suchy et al. 2013).
Ezetimibe as a lipophilic substance was dissolved in DMSO
to facilitate its introduction into the aqueous culture medium
(Cheng et al. 2009). The final concentration of DMSO in the
culture media (including those not supplemented with
ezetimibe solution) was equal to 0.05 % (v/v). The cells were
incubated for 48 h, after which cell culture supernates were
collected and the cells were harvested by vigorous pipetting
with ice-cold PBS. The cell culture supernates were centri-
fuged and immediately frozen at −80 °C. They were subse-
quently used for the determination of NO and IL-1β concen-
trations. The harvested cells from each well were divided into
two portions: one was subjected to Western blotting analysis
and the other to RT-PCR analysis in order to determine the
expression of iNOS, Arg1, and MR.
Assessment of cell viability
The viability of the cells was examined after the isolation of
monocytes from human whole-blood samples (to evaluate
their suitability for culture) and after harvesting the macro-
phages (to determine whether the results were affected by
disturbances during incubation). The viability was assessed
by staining the cells with trypan blue solution. The suspended
cells were incubated for 5 min in the above conditions with
Table 1 Sequences of primers used in the RT-PCR









Arg1 arginase-1, GAPDH glyceraldehyde 3-phosphate dehydrogenase,









Age ± SD (years) 53.6±3.9
Body mass index (kg/m2) 28.2±1.9
Cigarette smokers (%) 30.0
Total cholesterol (mg/dl) 263.4±12.5
LDL cholesterol (mg/dl) 179.7±11.3
HDL cholesterol (mg/dl) 43.1±2.5
Triglycerides (mg/dl) 123.9±11.4
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0.2 % (v/v) dye diluted in the cell culture medium. After that
time, the percentage of dead, blue-stained cells was counted
using a Bürker's chamber.
Assessment of NO production
The concentration of NO produced by the cells after different
stimulations was calculated as the sum of nitrites and nitrates,
which are its stable derivatives. The assessments were carried
out according to the instructions of the kit manufacturer.
Briefly, initially all the cell culture supernates were diluted
twofold. Next, the nitrates present in 80-μl samples were
reduced into nitrites with the use of nitrate reductase. The
amount of nitrites in the samples of culture media was deter-
mined through reaction with an equal volume of Griess re-
agent. After 10 min of incubation, the absorbances at 540 nm
were measured in a microplate reader (xMark Microplate
Spectrophotometer, Bio-Rad Laboratories, Inc., USA). Fresh
culture medium was used as a blank in all the measurements.
The amount of nitrites in the samples was calculated using the
calibration curve based on serial dilutions of sodium nitrite
standard.
Assessment of IL-1β secretion
The concentration of IL-1β produced by the cells after differ-
ent stimulations was measured using a commercially available
ELISA kit according to the manufacturer's instructions. Brief-
ly, 200-μl samples of cell culture supernates were incubated in
the anti-IL-1β-antibody-covered wells of a 96-well plate.
After washing the wells, equal volumes of antibody conjugate
were added. Subsequently, the wells were washed again and
substrate solutions were added. After stopping the reaction,
the absorbances at 450 nm (with correction at 540 nm) were
measured in a microplate reader (xMark Microplate Spectro-
photometer, Bio-Rad Laboratories, Inc., USA). The amount of
IL-1β in the samples was calculated using the calibration
curve based on serial dilutions of IL-1β standard.
Assessment of iNOS, Arg1, and MR mRNA expression
The expression of marker genes was analyzed using the RT-
PCR method. Total RNA was extracted with TRIzol reagent
according to the manufacturer's instructions based on a previ-
ously developed method (Chomczyński and Sacchi 1987).
The RNA extracts were supplemented with 2 μg of glycogen.
Reverse transcription was performed in a MJ Mini Personal
Thermal Cycler (Bio-Rad Laboratories, Inc., USA) with
0.5 μg total RNA using a cDNA synthesis kit according to
the manufacturer's instructions. RT-PCR was performed using
SYBR Green QPCR Master Mix with Low ROX with a RT-
PCR LightCycler 480 II (Roche Applied Science, USA). PCR
primers for iNOS (E.C. 1.14.13.39), Arg1 (E.C. 3.5.3.1), and
MR used in this study are listed in Table 1. Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH, E.C. 1.2.1.12) was used
as a reference gene. The relative expression values were
calculated using the comparative threshold cycle (ΔΔCt)
method.
Assessment of iNOS, Arg1, and MR protein expression
The expression of marker proteins was analyzed using the
Western blotting method. Whole-cell extracts were obtained
by lysing the cells with RIPA buffer with the addition of
protease inhibitors (104 mM AEBSF, 80 μM aprotinin,
4 mM bestatin, 1.4 mM E-64, 2 mM leupeptin, 1.5 mM
pepstatin A in the stock solution). The concentration of pro-
teins was assessed using Bradford's reagent (Bradford 1976)
by reading the absorbance at 595 nm in a microplate reader
(xMark Microplate Spectrophotometer, Bio-Rad Laborato-
ries, Inc., USA) and comparing the values with a calibration
curve based on serial dilutions of BSA. Equal amounts
(25 μg) of total proteins were run on SDS-PAGE (10 %
separating gel) in a Mighty Small II electrophoretic chamber
(Hoefer, USA) and transferred to a PVDF membrane in a
TE22 Mighty Small Transphor Unit (Hoefer, USA). The
membrane was blocked for 1 h at room temperature in 1 %
(v/v) BSA solution in Tris-buffered saline containing 0.08 %
(v/v) Tween 20 (TTBS). After blocking, the membrane was
incubated with subsequent specific primary antibodies (dilu-
tion 1:1,000) for 1 h at room temperature and further incubat-
ed for 1 h with a secondary antibody (dilution 1:10,000)
conjugated with horseradish peroxidase. The addition of sub-
strate solution resulted in the formation of a chemiluminescent
product. The chemiluminescence was read in a ChemiDoc-It
410 camera (UVP, USA) and analyzed densitometrically. β-
Actin was used as a reference protein. Independent expression
analyses of respective proteins (iNOS, Arg1, MR, and β-
actin) were preceded by membrane stripping to remove the
adsorbed primary antibodies.
Statistical analysis
The statistical analysis was performed with GraphPad Prism 6
for Windows (GraphPad Software Inc., USA). The normality
of continuous variable distributions was checked with the
Shapiro-Wilk's test. The results are presented as means ±
SD. Significant differences between experimental groups
were determined using the one-way ANOVA analysis with
Tukey's post hoc test. The homogeneity of variance, which is
an assumption of ANOVA, was checked with Brown-
Forsythe’s and Bartlett’s tests. The differences were consid-
ered significant at the level of p<0.05. The levels of signifi-
cance are marked as follows: *p<0.05, **p<0.01,
***p<0.001, and ****p<0.0001. The sample sizes (number
of replicates, n) are given with the relevant analysis results.
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The n values lower than 20 (approved by the Bioethical
Committee) resulted from independent external causes affect-
ing the performance of the experiment, resulting in the rejec-
tion of the whole series.
Results
The influence of culture preparation procedures and different
types of stimulation on the viability of the cells
The viability of isolated monocytes was assessed each time
before beginning a series of cultures. The mean viability of the
cells obtained from all the participants of the experiment (n=
20) was 96.42±3.35 %.
The viability of cultured cells, including the control cul-
tures, the cultures stimulated with LPS (1 μg/ml), and stimu-
lated with LPS (1 μg/ml) plus ezetimibe (22 ng/ml) (n=3 for
each), was tested at the beginning, during, and at the end of the
study. The mean viabilities of macrophages from the respec-
tive types of cultures were 95.08±5.09, 93.16±4.51, and
94.86±4.04. The given values were not significantly different
(p=0.9784), indicating that neither LPS nor ezetimibe at the
concentrations used affected the cell viability. The results of
viability testing also indicated that this parameter did not have
any influence on the outcome of the experiments.
LPS promotes the classical activation pathway
of monocyte-derived macrophages isolated
from hypercholesterolemic patients
The stimulation of macrophages with LPS significantly in-
creased expression of classical activation markers. LPS treat-
ment raised the total amount of nitrates and nitrites in the cell
culture supernates by 55% (Fig. 1). Additionally, we observed
an 18 % elevation in IL-1β concentration (Fig. 2). The in-
crease in NO production was accompanied by the upregula-
tion of its main producer, iNOS. The expression of the enzyme
was increased by more than twofold, both at the mRNA and
protein levels. In contrast, the levels of alternative macrophage
activation markers under the influence of LPS remained un-
affected with the exception of the expression of Arg1 protein,
which was significantly elevated. Concomitantly, the expres-
sion of Arg1 mRNAwas higher in comparison to the control
cells but the difference was not significant. The expression of
MR was not altered significantly. Both mRNA and protein
levels of MRwere about 15 % lower (Figs. 3, 4, and 5). These
observations suggest that LPS promotes the classical activa-
tion of macrophages obtained from hypercholesterolemic pa-
tients, which may resemble the state occurring in growing
atherosclerotic plaques.
Ezetimibe silences the classical activation pathway
of monocyte-derived macrophages isolated
from hypercholesterolemic patients
Co-stimulation of cultured macrophages with LPS and
ezetimibe decreased the expression of classical activation
markers. The most significant change regarded the expression
of iNOS mRNA and protein: the relative expression values
were decreased by over 50 % in comparison to the expression
Fig. 1 The influence of ezetimibe and/or LPS on the concentration of
NO derivatives. The cells were treated with LPS (1 μg/ml) or LPS
(1 μg/ml) plus ezetimibe (22 ng/ml) or were left untreated (control), for
48 h. The total concentration of nitrates and nitrites produced by the cells
was measured by the Griess reaction. Each value represents mean ± SD.
The sample size (n) represents the number of replicates measured for each
of the markers in each group in the given experiment. The levels of
significance are marked as follows: *p<0.05; **p<0.01; ***p<0.001;
****p<0.0001
Fig. 2 The influence of ezetimibe and/or LPS on the concentration of IL-
1β. The cells were treated with LPS (1 μg/ml) or LPS (1 μg/ml) plus
ezetimibe (22 ng/ml) or were left untreated (control), for 48 h. The
concentration of secreted IL-1β was assessed by ELISA. Each value
represents mean ± SD. The sample size (n) represents the number of
replicates measured for each of the markers in each group. The levels of
significance are marked as follows: *p<0.05; **p<0.01; ***p<0.001;
****p<0.0001. IL-1β interleukin-1β
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observed in LPS-stimulated cells. The expression of iNOS
mRNA and protein was comparable to that of control
macrophages (p=0.8260 and p=0.9862, respectively;
Figs. 3, 4, and 5). The reduction of iNOS expression
was accompanied by changes in NO secretion. The con-
centration of NO derivatives in the co-stimulated macro-
phages was 9 % lower than in the LPS-stimulated cells
(Fig. 1). However, the observed difference was not signif-
icant (p=0.5844). The amount of generated NO was sig-
nificantly higher (43 %) than in the control group, but the
difference was less significant (p<0.01 vs. p<0.001). Si-
multaneous stimulation of macrophages with LPS and
ezetimibe resulted in a 20 % reduction in the secretion
of IL-1β compared to the LPS-stimulated cells (Fig. 2).
The amount of the cytokine measured in the supernates
from the co-stimulated cells was comparable to that of the
control cells (6 % lower, p=0.6117). The above results
indicate that the addition of ezetimibe to the culture me-
dium silences the classical pathway of macrophage acti-
vation evoked by LPS.
Ezetimibe contributes to the alternative activation pathway
of monocyte-derived macrophages isolated
from hypercholesterolemic patients
The co-stimulation of macrophages with LPS and ezetimibe
increased the expression of alternative activationmarkers. The
addition of LPS to the medium resulted in the elevation of
Arg1 mRNA expression; however, it was the addition of
ezetimibe that induced a statistically significant change. The
expression of Arg1 mRNA in the co-stimulated cells was
42 % higher than in the control group. Also, the expression
of Arg1 protein was significantly increased (more than two-
fold) compared to the control cells. Of note, the expression of
Arg1 was only slightly higher than in the LPS-stimulated
macrophages. The most evident changes were observed re-
garding the MR. The expression of MR in the co-stimulated
cells compared to the control cells was 63 and 45 % higher at
the mRNA and protein levels, respectively. The elevation was
even more pronounced when compared to the LPS-stimulated
cells: the expression of the MR mRNA was almost twofold
higher and the expression of the MR protein was 66 % higher
(Figs. 3, 4, and 5). The noticed alterations suggest that
ezetimibe at the concentration that can be found in serum after
Fig. 3 The influence of ezetimibe and/or LPS on the mRNA expression
of macrophage activation markers. The cells were treated with LPS
(1 μg/ml) or LPS (1 μg/ml) and ezetimibe (22 ng/ml) or were left
untreated (control), for 48 h. The mRNA levels of iNOS, Arg1, and
MR were determined by RT-PCR and analyzed by the comparative
threshold cycle (ΔΔCt) method. GAPDH was used as a housekeeping
gene. Each value represents mean ± SD. The sample size (n) represents
the number of replicates measured for each of the markers in each group
in the given experiment. The levels of significance are marked as follows:
*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. GAPDH glyceralde-
hyde 3-phosphate dehydrogenase, iNOS inducible nitric oxide synthase,
Arg1 arginase-1, MR is mannose receptor
Fig. 4 The influence of ezetimibe and/or LPS on the protein expression
of macrophage activation markers. The cells were treated with LPS
(1 μg/ml) or LPS (1 μg/ml) plus ezetimibe (22 ng/ml) or were left
untreated (control), for 48 h. The protein levels of iNOS, Arg1, and MR
were determined by Western blotting and analyzed densitometrically. β-
Actin was used as a reference protein. Each value represents mean ± SD.
The sample size (n) represents the number of replicates measured for each
of the markers in each group. The levels of significance are marked as
follows: *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. iNOS induc-
ible nitric oxide synthase, Arg1 arginase-1, MR mannose receptor
Fig. 5 Representative Western blot image. Arg1 arginase-1, iNOS induc-
ible nitric oxide synthase, LPS lipopolysaccharide,MRmannose receptor
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chronic administration promotes the alternative activation of
macrophages obtained from hypercholesterolemic patients.
Discussion
Macrophages gathering in the arterial walls are key cells in the
pathogenesis of atherosclerotic lesions. Depending on their
activation type, macrophages may have opposing impacts on
the development and stability of plaques (Łabuzek et al. 2013;
McLaren et al. 2011). Atherosclerosis is a major complication
in hypercholesterolemia, and thus we decided to isolate mono-
cytes from newly diagnosed hypercholesterolemic patients.
During several days of incubation (Lovren et al. 2010; Zhou
and Amar 2007) and LPS stimulation (Lovren et al. 2010;
Panda et al. 2012), the monocytes were differentiated into
macrophages. The use of LPS at a submaximal concentration
of 1 μg/ml was intended to imitate the inflammatory state of
atherosclerotic lesions, to induce M1 polarization, and to
facilitate the determination of the qualitative and quantitative
effects of ezetimibe. In this way, the effect of priming the
macrophages with the chosen LPS concentration could poten-
tially be decreased or increased by the study drug. We decided
not to use commonmacrophage-differentiating factors such as
granulocyte-macrophage colony-stimulating factor (GM-
CSF) or macrophage colony-stimulating factor (M-CSF) as
they have been reported to induce M1 and M2 polarization,
respectively, but do not have a direct influence on
inflammatory-state generation (Fleetwood et al. 2009; Van
der Plas et al. 2009). We also did not use phorbol-12-
myristate-13-acetate (PMA) based on information that
ezetimibe impairs the differentiation process evoked by
PMA (Muñoz-Pacheco et al. 2012). Furthermore, we did not
evaluate the effect of ezetimibe alone as atherosclerosis is an
inflammatory disease and—being aware of the model's im-
perfections—we chose the co-stimulation to resemble the
actual conditions in which the drug is therapeutically used.
The markers used to determine the phenotype of macro-
phages were chosen based on their significance for the process
of atherogenesis and/or their credibility. IL-1β is not only a
well-accepted M1 macrophage marker but also contributes to
M1 macrophage generation. The cytokine also promotes
foam-cell formation because it reduces ABCA1/ABCG1
transporter mRNA expression and increases intracellular lipid
deposition. It was found to potentiate atherosclerotic changes
in mice in vivo (McLaren et al. 2011). iNOS is present in
tissues undergoing inflammatory processes, including athero-
sclerotic lesions, and its expression magnitude correlates with
severity of the disease. The in vitro experiments revealed that
NO produced by iNOS in activated macrophages causes apo-
ptotic and necrotic cell death (Tripathi 2007). Peroxynitrites
originating from NO induce protein nitration and apoptosis of
vascular smooth muscle cells (VSMCs), which in turn leads to
atherosclerotic plaque instability. Increased NO production in
M1 macrophages worsens atherogenic conditions. On the
other hand, iNOS expression blockade in hypercholesterol-
emic mice suppresses atherogenesis development (Feig and
Feig 2012). In turn, Arg1 is responsible for promitotic prop-
erties of M2 macrophages, i.e., inducing VSMC proliferation,
leading to increased atherosclerotic plaque stability. Arg1
competes with iNOS for the common substrate L-arginine
(L-Arg). Arg1 metabolizes L-Arg into L-ornithine, which is a
precursor of polyamines and proline. Polyamines play a cru-
cial role in cell growth, differentiation, and division, while
proline is a key component of collagen. Arg1 expression is
typical for theM2macrophages (Khallou-Laschet et al. 2010).
Arg1 is currently regarded as a new therapeutic target in
atherosclerosis prevention. In the experiments on animals, it
reduced atherosclerotic processes irrespective of the LDL
level. In contrast, generation of foam cells was linked with
suppression of Arg1 expression (Feig and Feig 2012). MRs
are reliable markers of alternative macrophage activation in
humans and mice (Martinez-Pomares 2012). It was observed
that macrophages expressingMRwere localized in regions far
from the lipidous necrotic core of atherosclerotic plaque but
their presence in the core itself was significantly lower. During
in vitro investigations, these macrophages were filled with
lipid droplets smaller than macrophages not expressing MR,
which demonstrated their decreased ability to scavenge LDL
and oxidized LDL and, in turn, their lower probability of
developing into foam cells (Chinetti-Gbaguidi et al. 2011).
By modulating macrophage activation, the dynamics of
atherosclerosis progression can be altered (Johnson and
Newby 2009; Khallou-Laschet et al. 2010). Previous investi-
gations proved that inhibition of the classical activation path-
way with CD40 antagonists and induction of the alternative
activation with peroxisome proliferator-activated receptor-γ
(PPARγ) agonists contributes to a restriction of atherosclerot-
ic processes (Lutgens et al. 2010; Sica and Mantovani 2012).
Considering these facts, we set out to assess the changes in the
expression of macrophage activation markers in order to de-
termine potential immunomodulative properties of ezetimibe,
which is used in hypercholesterolemia treatment, in terms of
the influence on atherosclerosis.
Numerous studies have demonstrated that stimulation of
monocytic cells of various origins (human, animal, cell lines)
with LPS results in an increase in IL-1β secretion (Netea et al.
2009; Okopień et al. 2005). In experiments on isolated human
monocytes/macrophages stimulated with LPS in conditions
similar to ours, the cells secreted comparable amounts of
cytokine (Okopień et al. 2005). However, the influence of
ezetimibe on IL-1β secretion in vitro is not well established.
Until now, the drug has been observed to reduce the secretion
of IL-1β in vivo (Alvarez-Sala et al. 2008; Undas et al. 2011).
Despite obtaining information on the systemic inflammatory
state in this way, it is not possible to precisely determine the
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source of the cytokine. In the experiments in which the pa-
tients were administered ezetimibe for 30 and 90 days, follow-
ed by isolation of monocytes, the secretion of the cytokine by
the cells was reduced by 17 and 18 %, respectively. However,
the observed differences were not statistically significant.
Only the addition of simvastatin to ezetimibe was found to
result in a significant reduction of IL-1β secretion (Krysiak
and Okopień 2011). Nevertheless, in these experiments,
ezetimibe was not used to stimulate the monocytes after
isolation, which might have affected the final outcome. In
recent in vitro experiments on isolated monocytes (Krysiak
and Okopień 2011; Moutzouri et al. 2012), cells were not
stimulated with ezetimibe thus interrupting their constant con-
tact with the drug. The investigations in this study allowed for
direct determination of the influence of ezetimibe on the IL-
1β level in the inflammatory conditions in vitro and con-
firmed that the drug reduces its secretion.
As in the case of IL-1β, information on the influence of
ezetimibe on the NO-iNOS-Arg1 balance is limited. Mostly,
the impact of the drug on the endothelial NOS (eNOS) iso-
form has been reported. In the animal model, ezetimibe
inhibited atherosclerosis progression and the effect was related
with marked eNOS mRNA and protein expression upregula-
tion (Nakagami et al. 2009). The data concerning iNOS ex-
pression was obtained in experiments on rats suffering from
nonalcoholic fatty liver disease. Administering ezetimibe to
the animals receiving a cholesterol-rich diet reduced liver
iNOS expression (Ibrahim et al. 2010), which is in agreement
with our results; however, the authors did not assess the
expression of the enzyme, in particular types of cells, and they
used whole-tissue homogenates.
Interestingly, in our experiments, ezetimibe did not influ-
ence the generated NO concentration in comparison to LPS
stimulation. Simultaneously, at the 48-h timepoint, the expres-
sion of iNOS was more than twofold lower. This may suggest
that LPS was initially predominant in the inflammatory reac-
tions, thus resulting in increased iNOS expression and NO
production. Next, during later timepoints of stimulation,
ezetimibe restricted iNOS expression, but the derivatives of
the generated NO still remained in the cell culture medium. As
the concentration of NO produced in the co-stimulated cul-
tures after 48 h was slightly (but not yet significantly) lower
than in the LPS-stimulated cultures and the iNOS expression
was markedly decreased, we conclude that this was probably
the moment from which the activity of the drug overwhelmed
the activity of LPS in this aspect. To confirm this, it will be
necessary to perform a time-dependent study of iNOS expres-
sion and NO production.
As in our experiments, it was previously noted that LPS
contributes to elevated Arg1 expression, which is an alterna-
tive macrophage activation marker (Rajaiah et al. 2013). It has
been established by other authors that LPS is a classical
macrophage activator. Despite this fact, they have also
observed that, to some extent, LPS contributes to increased
Arg1 expression. Furthermore, Arg1 expression in macro-
phages increases along with increasing LPS concentration
(Sonoki et al. 1997). Concomitant iNOS and Arg1 expression
upregulation is explained as a protection mechanism of the
cells from iNOS overexpression and toxic NO influence. Arg1
is considered to be an enzyme that limits the NO concentration
in the cell (Mielczarek-Puta et al. 2008). Interestingly, in our
study, ezetimibe did not significantly increase the expression
of Arg1 in the co-stimulated cells compared to the LPS
stimulation. We consider this effect to be related to the report-
ed lack of ezetimibe influence on the activity of the central
pro-inflammatory regulator nuclear factor-κB (NF-κB) in hu-
man mononuclear cells, expression of which markedly in-
creases after LPS treatment (Rudofsky et al. 2012). Apart
from the pro-inflammatory features of NF-κB, its phosphory-
lation also contributes to elevated Arg1 expression
(Mielczarek-Puta et al. 2008). This may explain the minor
influence of ezetimibe on Arg1 expression compared to the
LPS effect. However, the action of ezetimibe on NF-κB
requires further investigation. Finally, it should be noted that
for a significant increase in Arg1 mRNA expression, it was
necessary to stimulate the cells with both LPS and ezetimibe,
indicating that ezetimibe has an additional effect on the ex-
pression of this macrophage alternative activation marker.
The influence of LPS on the MR expression was insignif-
icant (Ferrante et al. 2013; Rajaiah et al. 2013), which we also
observed in our experiments. Importantly, elevated MR ex-
pression was noted in the alternatively activated macrophages
localized in the atherosclerotic plaques (Wilson 2010). As yet,
the influence of ezetimibe in vitro or in vivo on the expression
of this marker has not been assessed. Other pharmacologically
active substances such as eplerenone have demonstrated that
induction of alternative macrophage activation is related to
increased MR expression. Similarly to ezetimibe, the
mineralosteroid receptor antagonist, elevated the expression
of MR mRNA and protein in human monocyte-derived mac-
rophages (Łabuzek et al. 2013). Moreover, administering
eplerenone to Apo-E-knockout mice resulted in a restriction
of the area with early atherosclerotic changes in the arch of the
aorta, which was attributed to the change in the macrophage
phenotype towards alternative activation (Raz-Pasteur et al.
2012). We observed that ezetimibe strongly increased MR
expression in human monocyte-derived monocytes in vitro.
The quantitative and qualitative effects of macrophage
stimulation by LPS observed in our study were similar to
those noted in recent studies. This study is the first assessment
of the influence of ezetimibe on the magnitude of macrophage
activation marker expression. We confirmed that the drug
presents anti-inflammatory properties, in particular resulting
from a direct influence on macrophages. It can be assumed
that ezetimibe may exert a local anti-inflammatory effect in
growing atherosclerotic plaques, where the macrophages
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reside. We also presume that in the in vivo conditions—in
which the atherosclerotic plaque is affected by constantly
circulating fluids—the NO, once produced, would not accu-
mulate locally. As further production of NO would be ham-
pered due to decreased iNOS expression caused by ezetimibe,
generation of reactive nitrogen species (RNS), which contrib-
ute to the modification of LDLs, would also be restricted.
Therefore, the drug is probably able to restrict atherogenic
conditions, stating an extra-lipid effect. Additionally,
ezetimibe is likely to alter transmembrane trafficking due to
reduction of MR expression. The drug may then not only
effectively decrease the LDL level but may also exert a direct
extra-lipid effect on the cells taking part in atherosclerotic
plaque growth and stability modulation. Partial in vivo con-
firmation of the outcome of our investigations was observed in
the experiments on rabbits. Administering ezetimibe to the
animals resulted in the reduction of the atherosclerotic change
areas in the femoral arteries. The drug also decreased the
number of macrophages and the expression of monocyte
chemoattractant protein-1 (MCP-1) in the atherosclerotic
plaques. Additionally, ezetimibe was observed to reduce
lipid-rich areas, preserving the collagen content (Gómez-
Garre et al. 2009).
The analyzed markers are essential for the determination of
macrophage activation pathways and also have an influence
on atherosclerotic plaque stability. However, the biochemical
mechanisms of macrophage phenotype alternation by
ezetimibe still remain vague. Based on our current knowledge,
macrophage phenotype modulation by ezetimibe might be
due to its influence on the expression of Toll-like receptors
(TLRs). The drug decreases TLR2 and TLR4 expression in
the cell membranes of hypercholesterolemic patients. Signal-
ing via both the receptors promotes inflammatory responses
and progression of atherosclerosis. Furthermore, TLR2 and
TLR4 expression is elevated in the monocytes of atheroscle-
rotic patients (Moutzouri et al. 2012). Investigation of further
activation markers such as tumor necrosis factor alpha, IL-6,
IL-12, and reactive oxygen species for the classical activation
and IL-10, tumor growth factor-β1, and prostaglandin-E2 for
the alternative activation would be helpful to clarify the effect
of ezetimibe and elucidate its potential mechanism.
Conclusions
In summary, our study indicates that ezetimibe, used in vitro at
a concentration that occurs in serum, is likely to induce the
alternative activation of monocyte-derived macrophages iso-
lated from patients with hypercholesterolemia, concomitantly
suppressing the classical activation. Earlier studies addition-
ally demonstrated that the drug increases the stability of
atherosclerotic plaques in animals. Taken together, it is prob-
able that the substance may stabilize the plaques in
hypercholesterolemic patients. It is essential to carry out fur-
ther clinical studies to assess the latter.
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